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Aims Vascular smooth muscle cell (VSMC) apoptosis can lead to thinning of the ﬁbrous cap and plaque instability. We
previously showed that cell–cell contacts mediated by N-cadherin reduce VSMC apoptosis. This study aimed to
determine whether matrix-degrading metalloproteinase (MMP)-dependent N-cadherin cleavage causes VSMC
apoptosis.
Methods
and results
Induction of human VSMC apoptosis using different approaches, including 200 ng/mL Fas ligand (Fas-L) and culture in
suspension, caused N-cadherin cleavage and resulted in the appearance of a C-terminal fragment of N-cadherin
(35 kDa). Appearance of this fragment during apoptosis was inhibited by 47% with the broad-spectrum MMP inhibi-
tor BB-94. We observed retarded cleavage of N-cadherin after treatment with Fas-L in aortic mouse VSMCs lacking
MMP-7. Furthermore, VSMC apoptosis, measured by quantiﬁcation of cleaved caspase-3, was 43% lower in MMP-7
knockout mouse VSMCs compared with wild-type VSMCs following treatment with Fas-L. Addition of recombinant
active MMP-7 increased the amount of N-cadherin fragment by 82% and augmented apoptosis by 53%. The involve-
ment of MMP-7 was corroborated using human cells, where a MMP-7 selective inhibitor reduced the amount of
fragment formed by 51%. Importantly, we observed that treatment with Fas-L increased levels of active MMP-7 by
80%. Finally, we observed signiﬁcantly increased cleavage of N-cadherin, MMP-7 activity, and apoptosis in human
atherosclerotic plaques compared with control arteries, and a signiﬁcant reduction in apoptosis in atherosclerotic
plaques from MMP-7 knockout mice.
Conclusion This study demonstrates that MMP-7 is involved in the cleavage of N-cadherin and modulates VSMC apoptosis, and
may therefore contribute to plaque development and rupture.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Rupture of atherosclerotic plaques is the major cause of myocardial
infarction and stroke.
1 Vascular smooth muscle cells (VSMCs) form
a protective ﬁbrous cap over atherosclerotic plaques. VSMC apopto-
sis in the ﬁbrous cap
2 and subsequent weakening of the cap
3 is
thought to be an important regulator of plaque stability. In normal
blood vessels VSMC apoptosis is rare, however increased apoptosis
is observed in unstable human atherosclerotic plaques.
4 Recently,
mouse models of atherosclerosis have provided direct evidence that
VSMC apoptosis causes plaque instability.
5–7 Consequently, reducing
VSMC apoptosis is an attractive strategy for attenuating plaque
instability. A greater understanding of the mechanisms underlying
apoptosis of VSMCs in the ﬁbrous cap may aid the development of
new therapies for reducing plaque instability.
We have previously demonstrated that N-cadherin, a predominant
cell–cell junction protein in VSMCs,
8 provides a vital pro-survival
signal to VSMCs via PI3-kinase-dependent activation of Akt.
9 Over-
expression of N-cadherin reduced apoptosis of VSMCs in suspension
culture, while conversely, over-expression of dominant negative
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showed that a soluble form of N-cadherin, composed of the extra-
cellular domain, acts as a mimetic reducing VSMC apoptosis, as well
as features of atherosclerotic plaque instability in vivo.
10
Studies in other cell types have suggested that cadherin cleavage by
matrix-degrading metalloproteinases (MMPs) or a disintegrin and
metalloproteases (ADAMs) occurs during apoptosis.
11–14 Although
we have previously observed that MMPs, speciﬁcally MMP-9 and
MMP-12, cleave N-cadherin during VSMC proliferation,
8,15 it was
unknown whether MMP-dependent cleavage of N-cadherin modu-
lates VSMC apoptosis. We therefore aimed to determine whether
proteolytic cleavage of N-cadherin by MMPs leads to VSMC apoptosis
and is therefore likely to contribute to plaque development and
rupture.
2. Methods
2.1 Husbandry
Knockout mice were kindly provided by Roger Lijnen (University of
Leuven, Belgium) and then bred within the University of Bristol animal
unit. C57BL/6J mice were obtained from Charles River and used as wild-
type controls. Apolipoprotein E knockout mice (ApoE
2/2) were crossed
with MMP-7 knockout mice to generate ApoE
2/2/MMP-7
2/2 as well as
strain-matched controls (ApoE
2/2/MMP-7
þ/þ). These mice were placed
on high-fat diet for 8 weeks and brachiocephalic arteries removed as pre-
viously described.
16 Housing, care, and all procedures were performed in
accordance with the guidelines and regulations of the University of Bristol
and the United Kingdom Home Ofﬁce. The investigation conforms to the
Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised 1996).
2.2 Cell culture
The investigation conforms to the principles outlined in the Declaration of
Helsinki. Human saphenous vein segments were obtained from consenting
coronary artery bypass graft patients (Local ethics board REC#05/Q2007/
77) and VSMCs grown from medial explants as described previously.
8
Mouse VSMCs were grown from explants of mouse aorta removed
from either MMP knockout or wild-type mice or C57BL/6J controls, as
described previously.
15 Each experiment was performed with VSMCs at
passage 2–10 from at least three different individuals.
Apoptosis was induced either by culturing VSMCs (5   10
4 cells/well in
24 well plates) in serum free media supplemented with 300 ng/mL human
recombinant soluble Fas ligand (Fas-L), 50 ng/mL tumour necrosis
factor-a (TNFa), 100 mMH 2O2 or 50 mM BCl2 antagonist (HA-14, Cal-
biochem), or by culturing VSMCs in suspension culture as described
previously.
17
MMP activity was inhibited by 1 mM BB-94 (Batimastat, a widely used
and speciﬁc MMP inhibitor which inhibits many MMPs including MMPs
1, 2, 3, 7, 9, 12, 13 with Ki values of 0.15–2.3 nM,
18 was a kind gift of
Dr Clive Long, Pﬁzer), 2 mM MMP-2 inhibitor
19 (Ki values of 1.7 mM for
MMP-2, 444244, Calbiochem), 100 nM MMP-12 inhibitor
20,21 (IC50
14 nM for MMP-12 and .270 nM for MMPs 2, 3, 8, 9, and 13,
PF-356231, Biomol), or 10 nM MMP-7 inhibitor (IC50 10 nM for MMP-7,
444264, Calbiochem). g-Secretase, plasmin, and caspase activity were
inhibited by 10 mM g-secretase inhibitor (565771, Calbiochem), 10 mM
NALME
22,23 (Sigma), and 20 mM pan caspase inhibitor (Z-VAD-FMK)
inhibitor (550377, Calbiochem), respectively. DMSO was added to act
as a vehicle control in all experiments. VSMCs were also treated with
60 nM active recombinant human MMP-7 (444270 Calbiochem) and
2 mg/mL cycloheximide (to prevent protein synthesis and thereby
inhibit replenishment of full-length N-cadherin).
2.3 Atherosclerotic plaques
Human carotid endarterectomy samples were obtained (local ethical
approval #E3111) as described previously.
24 Human right coronary
artery plaques were removed from hearts collected for valve retrieval
(local ethical approval REC#08/H0107/48). Surplus segments of internal
mammary artery (IMA) were obtained from consenting patients under-
going coronary artery bypass grafting (local ethical approval REC#04/
Q2007/6). Frozen samples were extracted in SDS lysis buffer or MMP-7
assay buffer (1 mM monothioglycerol, 50 mM Tris–HCl, pH 7.4) and ana-
lysed by western blotting and MMP-7 activity assay, respectively, or frozen
sections were cut for in situ zymography.
2.4 Cleavage of recombinant N-cadherin by
MMP-7
As described previously,
15 active MMP-7 (2 nM) was incubated with 2 nM
puriﬁed soluble N-cadherin-Fc (SNC-Fc; consisting only of the extracellu-
lar domain), for 30 min at 378C and then subjected to western blotting.
2.5 Western blotting
Western blotting for N-cadherin, phosphorylated Akt (pAkt), total Akt,
and b-tubulin was performed with equal protein concentrations, as
described previously.
8,9 The anti-N-cadherin antibody (610920, BD Trans-
duction Laboratories) recognizes amino acids 802–819 in the C-terminus
of N-cadherin. To detect SNC-Fc, western blotting for the Fc domain of
mouse IgG was performed as described previously.
15 Cleaved caspase-3
was detected using rabbit anti-cleaved caspase-3 antibody diluted
1:1000 (Cell Signalling No. 9661). Densitometric scanning was performed
to quantify the optical density of detected bands (O.D.   mm
2) and nor-
malized to b-tubulin values.
2.6 Measurement of apoptosis
Apoptosis was assessed in vitro by measurement of cleaved caspase-3
levels using the Caspase-Glo luminescent assay (Promega) as described
in the manufacturer’s instructions. Immunocytochemistry for cleaved
caspase-3 was performed as described previously.
10 Apoptosis was also
measured in parafﬁn-wax embedded sections using in situ end labelling
(ISEL) as described previously.
25 The number of ISEL positive plaque
cells was counted and expressed as a percentage of the total number
of plaque cells.
2.7 MMP-7 activity assay
Ten times concentrated conditioned media and tissue lysates were
assessed for MMP-7 activity using a ﬂuorimetric assay. Samples and stan-
dards were incubated with 0.14 mg/mL DQ-gelatin ﬂuorescent substrate
(Invitrogen) with and without 10 nM MMP-7 inhibitor (444264, Calbio-
chem) and ﬂuorescence read using a Fluostar Optima ﬂuorimeter from
0 to 90 min until peak ﬂuorescence was achieved. MMP-7 activity was
calculated as that inhibited by the MMP-7 inhibitor.
2.8 In situ zymography
MMP activity was detected as described previously.
26 Sections were incu-
bated with 10 nM MMP-7 inhibitor to identify MMP-7 activity. In some
cases, immunohistochemistry for cleaved caspase-3 was performed as
described previously
10 after in situ zymography. MMP activity was quanti-
ﬁed using image analysis and expressed as ﬂuorescent arbitrary units
(FAU).
2.9 Statistics
Experiments were carried out at least three times with VSMCs from
different sources. Data were analysed by Student’s t-test or ANOVA
and Student Newman–Keuls post-test and a signiﬁcant difference
accepted when P , 0.05.
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3.1 N-cadherin is cleaved during VSMC
apoptosis
Treatment with Fas-L resulted in a time-dependent cleavage of full-
length N-cadherin in human VSMCs (Figure 1A), which reached signiﬁ-
cance after 4 h of treatment (Figure 1B). The appearance of 35 kDa
fragment of N-cadherin was also observed after 4 h (Figure 1A and C).
Other inducers of apoptosis (Bcl2 antagonist, TNFa,H 2O2, or sus-
pension culture) also caused cleavage of full-length N-cadherin and
the appearance of the 35 kDa N-cadherin fragment (Figure 1D),
conﬁrming that this was not a unique effect of Fas-L-induced
apoptosis. Using western blotting, we were unable to detect release
of the extracellular domain of N-cadherin into the conditioned
media (data not shown).
3.2 MMPs contribute to N-cadherin
cleavage
Addition of the MMP inhibitor BB-94 (Figure 2A) signiﬁcantly reduced
the amount of N-cadherin fragment produced in response to Fas-L
and increased full-length N-cadherin correspondingly, indicating that
MMPs are involved in N-cadherin cleavage. In contrast, N-cadherin
cleavage was not retarded by treatment of human VSMCs with a
plasmin inhibitor (NALME) with or without BB-94 (see
Figure 1 N-cadherin cleavage occurs during VSMC apoptosis. Representative western blot for full-length (FL, 130 kDa) and 35 kDa C-terminal
fragment of N-cadherin protein in human VSMCs after induction of apoptosis with Fas-L at various time-points (A), full-length N-cadherin at 4 h (B),
and 35 kDa C-terminal fragment of N-cadherin after 4 h (C). Bar charts show densitometric analysis of western blots (B and C) and * indicates a
signiﬁcant difference (P , 0.05) from control, n ¼ 5. (D) Representative western blot for full-length (130 kDa) and 35 kDa C-terminal fragment of
N-cadherin protein in human VSMCs after induction of apoptosis with 50 mM Bcl2 antagonist (Bcl2 antag) for 18 h, 100 mMH 2O2, or 50 ng/mL TNFa
for 22 h, and suspension culture for 24 h. b-Tubulin is shown as loading control.
MMP-7 induces N-cadherin cleavage and VSMC apoptosis 139Figure 2 N-cadherin cleavage during apoptosis is mediated by MMPs. (A) Representative western blots (n ¼ 6) for N-cadherin protein in human
VSMCs 4 h after the addition of Fas-L and 1 mM BB-94 or DMSO (vehicle control). (B) Representative western blots (n ¼ 3) N-cadherin protein in
mouse wild-type VSMCs 4 h after the addition of Fas-L with or without 1 mM BB-94 or DMSO vehicle control. (C) Representative western blots
(n ¼ 3) for N-cadherin protein in mouse wild-type or MMP-3, -7, -9, or -12 knockout VSMCs 4 h after the addition of Fas-L. (D) Representative
western blots (n ¼ 3) for N-cadherin protein in mouse MMP-7 knockout VSMCs 4 h after the addition of Fas-L with or without 1 mM BB-94 or
DMSO vehicle control. Bar charts (A, B, and C) show densitometric analysis of western blots for 35 kDa C-terminal fragment of N-cadherin,
data are shown as percent of control, and * and $ indicate a signiﬁcant difference (P , 0.05) from control and Fas-L þ DMSO, respectively.
b-Tubulin is shown as loading control. (E) Cleaved caspase-3 activity expressed as LAU in mouse wild-type or MMP-3, -7, -9, or -12 knockout
(KO) VSMCs 8 h after the addition of Fas-L. * indicates a signiﬁcant difference (P , 0.05) from wild-type control, n ¼ 6.
H. Williams et al. 140Supplementary material online, Figure S1) or with a caspase inhibitor
or g-secretase inhibitor (data not shown).
3.3 MMP-7 contributes to N-cadherin
cleavage and apoptosis
To identify which MMP was responsible for N-cadherin cleavage, we
used aortic VSMCs isolated from a selection of MMP knockout mice.
We ﬁrst ensured that we obtained the same effect in wild-type
(C57BL/6J) mouse VSMCs as observed in human VSMCs. As seen
in human VSMCs, we observed a signiﬁcant increase in N-cadherin
fragment and a decrease in full-length N-cadherin in mouse VSMCs
following Fas-L treatment, and this increase was inhibited by BB-94
(Figure 2B). Increased N-cadherin fragment and decreased full-length
N-cadherin levels were also observed in VSMCs from MMP-3,
MMP-9, and MMP-12 knockout mice after treatment with Fas-L
(Figure 2C). However, this was not observed in VSMCs from MMP-7
knockout mice (Figure 2C and D). Importantly, we observed that
basal levels of full-length N-cadherin in the various cell types used
were comparable (wild-type controls: 15.3+3.1, MMP-3
2/2:
15.9+1.1, MMP-7
2/2: 14.5+1.6, MMP-9
2/2: 15.0+3.8, and
MMP-12
2/2: 14.0+2.7, O.D.   mm
2, Figure 2C). Additionally, there
was no difference in N-cadherin cleavage in the different wild-type
VSMCs compared with the C57BL/6J control cells (see Supplemen-
tary material online, Figure S2). Furthermore, supplementation with
BB-94 did not signiﬁcantly affect the amount of N-cadherin fragment
detected after Fas-L treatment of MMP-7 knockout VSMCs
(Figure 2D).
Cleaved caspase-3 activity was measured 8 h after induction of
apoptosis with Fas-L using the Caspase-Glo assay. Cleaved
caspase-3 was signiﬁcantly reduced in MMP-7 knockout VSMCs
compared with control VSMCs (Figure 2E). In contrast, there was
no statistical difference in cleaved caspase-3 in VSMCs from MMP-3,
-9, and -12 knockouts compared with controls. Due to a large
Figure 3 MMP-7 promotes N-cadherin cleavage and apoptosis. Representative Western blots for full-length N-cadherin (A), and 35 kDa C-
terminal fragment of N-cadherin (B) at 4 h after addition of 60 nM recombinant MMP-7. b-Tubulin is shown as loading control. Bar charts show den-
sitometric analysis of western blots (A and B), data are shown as % of control and * indicates a signiﬁcant difference (P , 0.05) from control, n ¼ 6.
Cleaved caspase-3 activity in human VSMCs treated with MMP-7 for 24 h (C), * indicates a signiﬁcant difference (P , 0.05) from control, n ¼ 3.
MMP-7 activity in human VSMC conditioned media with or without Fas-L for 4 h (D), * indicates a signiﬁcant difference (P , 0.05) from control,
n ¼ 4. (E) Representative western blot for Fc domain of mouse IgG after 30 min incubation of 2 nM MMP-7 with 2 nM recombinant N-cadherin
(SNC-Fc).
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mined the effect of a MMP-12 inhibitor on cleaved caspase-3 activity.
No difference in cleaved caspase-3 activity was observed [699316+
288179 vs. 690540+258043 luminescent arbitrary units (LAU)].
We investigated whether addition of a human recombinant MMP-7
affected N-cadherin cleavage and apoptosis. Addition of recombinant
MMP-7 caused a signiﬁcant increase in cleavage of N-cadherin, as
shown by a reduction in full-length N-cadherin (Figure 3A) and pro-
duction of the 35 kDa fragment (Figure 3B). Cycloheximide
(which was added to all conditions to inhibit replenishment of
N-cadherin by protein synthesis) alone had no signiﬁcant effect on
N-cadherin levels compared with control (data not shown). Increased
N-cadherin cleavage was associated with signiﬁcantly augmented
apoptosis (Figure 3C). To establish whether MMP-7 activity is
increased during Fas-L induced apoptosis, we measured MMP-7 in
the conditioned media of Fas-L-treated VSMCs. MMP-7 activity was
signiﬁcantly increased in Fas-L treated VSMCs (Figure 3D), conﬁrming
that MMP-7 activity is elevated during VSMC apoptosis. To establish
whether the cleavage of N-cadherin by MMP-7 is direct or indirect,
recombinant N-cadherin was incubated with active MMP-7. We
observed that cleavage of N-cadherin occurred in the absence of
cells and other proteases and therefore is direct (Figure 3E).
Figure 4 MMP-7 inhibitor (MMP-7i) retards N-cadherin cleavage and VSMC apoptosis. (A) Representative western blot (n ¼ 3) for full length and
35 kDa C-terminal fragment of N-cadherin protein in human VSMCs 4 h after the addition of Fas-L with or without 10 nM MMP-7 inhibitor
(MMP-7i). (B) Representative western blot (n ¼ 3) for full length and 35 kDa C-terminal fragment of N-cadherin protein in mouse wild-type
VSMCs grown in suspension (Susp) to induce apoptosis and treated with 10 nM MMP-7 inhibitor. Bar charts (A and B) show densitometric analysis
of western blots, data are shown as percent of control and * indicates a signiﬁcant difference (P , 0.05) from Fas-L or suspension culture alone. (C)
Cleaved caspase-3 activity in human VSMCs treated with Fas-L with or without 10 nM MMP-7 inhibitor for 8 h, * indicates a signiﬁcant difference
(P , 0.05) from Fas-L alone, n ¼ 4. (D) Representative western blots (n ¼ 3) for pAkt, and total Akt. Bar chart shows densitometric analysis of
western blots, data are shown as percent of control and * and $ indicate a signiﬁcant difference (P , 0.05) from control and Fas-L, respectively.
b-Tubulin is shown as loading control. All control samples were supplemented with DMSO to act as a vehicle control.
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and VSMC apoptosis, we utilized a MMP-7 inhibitor. Apoptosis was
induced in both human and mouse VSMCs using Fas-L and suspension
culture,respectively,andinbothcasestheMMP-7inhibitorsigniﬁcantly
reduced the amount of N-cadherin fragment and increased full-length
N-cadherin (Figure 4A and B). Interestingly, the degree of inhibition of
N-cadherin fragment formation observed with the MMP-7 inhibitor
was comparable to that seen with BB-94 (Figure 4B), which suggests
that MMP-7 is the primary MMP involved in N-cadherin cleavage. No
further inhibition of N-cadherin cleavage was observed with
co-treatment with the MMP-7 inhibitor and the plasmin inhibitor
NALME (see Supplementary material online, Figure S1). Addition of a
MMP-2inhibitorhadnosigniﬁcanteffect (datanotshown).Toascertain
whether reduced N-cadherin cleavage was associated with attenuated
apoptosis in human VSMCs, cleaved caspase-3 was measured. As
seen in the MMP-7 knockout mouse VSMCs, inhibition of MMP-7 in
human VSMCs resulted in a signiﬁcant reduction in cleaved caspase-3
following addition of Fas-L (Figure 4C). Fas-L caused a signiﬁcant
decline in pAkt, whereas signiﬁcantly elevated levels of pAkt were
observed when VSMCs were treated with the MMP-7 inhibitor and
Fas-L (Figure 4D). In contrast, active MMP-7 reduced pAkt levels
(Figure 4D).
3.4 N-cadherin, apoptosis, and MMP-7
in atherosclerotic plaques
Human carotid and coronary arterial plaques and IMAs were sub-
jected to western blotting to examine N-cadherin and cleaved
caspase-3 protein expression (Figure 5A and B). Full-length N-cadherin
protein was seen in both atherosclerotic plaques and healthy arteries,
however signiﬁcantly lower levels of full-length N-cadherin was
detected in plaques compared with IMA (Figure 5A). Moreover,
cleaved N-cadherin was only detected in the atherosclerotic arteries
(Figure 5A). Cleaved caspase-3 was also signiﬁcantly higher in athero-
sclerotic plaques compared with IMAs (86+33 vs. 4+2 O.D.  
mm
2, Figure 5B). Additionally, MMP-7 activity was signiﬁcantly higher
in atherosclerotic plaques than IMAs (Figure 5C).
We assessed MMP activity using in situ zymography. We observed
MMP activity in atherosclerotic plaques while little MMP activity was
detected in IMAs (1681+518 vs. 37+12 FAU, Figure 6A and D).
A signiﬁcant amount of the MMP activity was mediated by MMP-7
since MMP activity was signiﬁcantly reduced by 70% with the
MMP-7 inhibitor (571+218 vs. 1681+518 FAU, Figure 6A and B).
Apoptotic cells were co-located in areas of MMP activity in athero-
sclerotic plaques, whereas MMP activity and apoptosis were low in
IMAs (Figure 6C–E).
Apoptosis was quantiﬁed in mouse brachiocephalic plaques using
ISEL. The percentage of apoptotic plaque cells was signiﬁcantly
lower in atherosclerotic plaques from ApoE
2/2/MMP-7
2/2 mice
than ApoE
2/2/MMP-7
þ/þ mice (0.05+0.01 vs. 0.12+0.03%,
Figure 6F–H).
4. Discussion
This study demonstrates a link between MMP-7, N-cadherin cleavage,
and VSMC apoptosis in atherosclerotic plaques. We have shown
in vitro that during apoptosis, levels of active MMP-7 are elevated
and that augmented levels of MMP-7 activity are associated with
N-cadherin cleavage and increased apoptosis. Furthermore, we have
shown increased MMP-7 activity, apoptosis, and N-cadherin cleavage
in atherosclerotic plaques.
Although VSMC apoptosis is rare in normal blood vessels,
increased apoptosis is observed in unstable human atherosclerotic
plaques
4 and promotes plaque instability in mouse models of athero-
sclerosis.
5–7 We previously demonstrated that N-cadherin acts as
Figure 5 N-cadherin, MMP-7, and apoptosis in human IMA and atherosclerotic plaques. Representative western blot for N-cadherin (A) and cleaved
caspase-3 (B) in IMA and coronary and carotid atherosclerotic plaques, n ¼ 3 per group. b-Tubulin is shown as loading control. Bar chart in (A) shows
densitometric analysis of N-cadherin western blots. (C) MMP activity in IMA and atherosclerotic plaques, n ¼ 15 and 20. * indicates a signiﬁcant differ-
ence from IMA.
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9 and soluble N-cadherin reduces features
of plaque instability.
10 In this study, we examined whether proteolytic
cleavage of N-cadherin occurs and contributes to VSMC apoptosis.
We observed a time-dependent loss of full-length N-cadherin and
appearance of a C-terminal fragment of N-cadherin (35 kDa)
after induction of human VSMC apoptosis with various factors includ-
ing Fas-L, suspension culture, or TNFa. The appearance of the
35 kDa fragment consisting of the intracellular and transmembrane
portion of N-cadherin indicates extracellular cleavage. Previously a
38 kDa fragment N-cadherin was reported to be the result of MMP
activity and was further processed by presenilin/g-secretase to
33 kDa.
27 However, we were unable to determine any cleavage by
presenilin/g-secretase. Additionally, we were unable to detect
release of the extracellular domain into the conditioned media as
seen previously for E-cadherin,
28 presumably due to further proteo-
lytic cleavage of the extracellular fragment of N-cadherin.
Previous studies have highlighted cleavage of cadherins by various
proteases including calpain,
29 ADAMs,
27 plasmin,
30 presenilin-1/
g-secretase,
14 and MMPs.
13,28,31–34 During tumour regression,
increased apoptosis was accompanied by elevated MMP activity and
E-cadherin cleavage.
32 Similarly, Herren et al.
13 showed
MMP-dependent cleavage of VE-cadherin during endothelial cell
apoptosis. Wu and Huang
31 identiﬁed that snake venom metallopro-
teinases cause activation of MMP-2, cleavage of VE-cadherin, and
Figure 6 MMP-7 and apoptosis in atherosclerotic plaques. In situ zymography of coronary atherosclerotic plaque in the absence (A) and presence
(B) of 10 nM MMP-7 inhibitor. Green colour indicates MMP activity and nuclei are stained blue with DAPI. Dual detection of cleaved caspase-3 (red)
and MMP activity (green) in coronary plaque (C) and IMA (D). (E) High power image of marked area in (C), arrows indicate co-location of apoptosis
and MMP activity. (F) Quantiﬁcation of the percentage of apoptotic (ISEL positive) cells in atherosclerotic plaques from ApoE
2/2/MMP-7
þ/þ and
ApoE
2/2/MMP-7
2/2. * indicates a signiﬁcant difference from ApoE
2/2/MMP-7
þ/þ. ISEL staining of atherosclerotic plaques from ApoE
2/2/
MMP-7
þ/þ (G) and ApoE
2/2/MMP-7
2/2 (H) mice. ISEL positive apoptotic cells are green and nuclei are stained blue (DAPI).
H. Williams et al. 144apoptosis of endothelial cells. Furthermore, N-cadherin cleavage
during activated hepatic stellate cell apoptosis is promoted by
MMP-2
35 and inhibited by the endogenous inhibitor of MMPs
(TIMP-1).
12 In our study, combined treatment with Fas-L and a
global non-speciﬁc MMP inhibitor signiﬁcantly reduced N-cadherin
cleavage, while plasmin, caspase, and g-secretase inhibitors had no
effect, indicating that MMP activity is involved in N-cadherin cleavage.
Using VSMCs from MMP knockout mice, we identiﬁed a role for
MMP-7 in the cleavage of N-cadherin during VSMC apoptosis. In
support of this, addition of recombinant active MMP-7 caused loss
of full-length N-cadherin, appearance of the N-cadherin fragment,
and increased apoptosis in human VSMCs while a MMP-7 inhibitor
reduced Fas-L-induced N-cadherin cleavage and apoptosis in human
VSMCs. Incubation of recombinant N-cadherin with MMP-7 revealed
that cleavage of N-cadherin was direct and did not require the pres-
ence of other proteases. Interestingly, we also showed that as a result
of Fas-L treatment, MMP-7 activity is augmented in human VSMCs.
We observed that as a result of N-cadherin cleavage, pAkt levels
were reduced, conﬁrming our previous ﬁnding that N-cadherin acts
as a survival signal via activation of Akt.
9 Together this data clearly
indicates that MMP-7 contributes to the cleavage of N-cadherin and
the induction of VSMC apoptosis. Although previous studies have
shown that MMP-7 cleaves E-cadherin,
28,34 this is the ﬁrst demon-
stration that MMP-7 can cleave N-cadherin. Recently, we observed
that MMP-9- and MMP-12-dependent cleavage of N-cadherin occurs
during VSMC proliferation.
15 Interestingly, in this study, we observed
no involvement of MMP-9 and MMP-12 in N-cadherin cleavage during
VSMC apoptosis. This indicates that different MMPs are responsible
for N-cadherin cleavage during these different cellular processes of
proliferation and apoptosis.
Polymorphisms of MMP-7 have been associated with coronary
artery disease.
36 Moreover although MMP-7 is absent in control
arteries, it is present in atherosclerotic plaques.
37 More speciﬁcally,
MMP-7 was expressed speciﬁcally in lipid-laden macrophages con-
ﬁned to the sites susceptible to rupture; the border between the acel-
lular lipid cores and the ﬁbrous areas.
37 They proposed therefore that
MMP-7, speciﬁcally expressed in atherosclerotic lesions, could cleave
structural proteoglycans including versican, potentially leading to sep-
aration of caps and shoulders from lipid cores and plaque instability.
Additionally, ApoE
38 and apolipoprotein C-II
39 are substrates for
MMP-7 which will affect atherosclerotic plaque formation and stab-
ility. We observed elevated MMP-7 activity in atherosclerotic
plaques compared with controls, which correlated and co-located
with increased apoptosis and N-cadherin cleavage. We therefore
suggest that in addition to matrix and apolipoprotein cleavage,
MMP-7 further contributes to plaque instability by induction of apop-
tosis of VSMCs as a result of N-cadherin cleavage. MMP-7 may also
exert a pro-apoptotic effect through other proteolytic mechanisms.
For example, it has been shown that MMP-7 can cleave Fas-L, releas-
ing soluble Fas-L and thus facilitating Fas-induced apoptosis.
40 Indeed,
in our study, we have utilized this well characterized death pathway as
an apoptotic stimulus. Moreover, as stated earlier, MMP-7 has numer-
ous other substrates which are present in atherosclerotic plaques and
which cleavage of may inﬂuence cell survival.
Deletion of MMP-7 in ApoE knockout mice led to a 78% increase in
VSMC content of the plaque.
16 We demonstrated in this study that
MMP-7 deﬁciency attenuated apoptosis, indicating that MMP-7 plays
a pro-apoptotic role in atherosclerotic plaques in vivo. Despite the
increased numbers of VSMCs in atherosclerotic plaques of MMP-7
knockout mice however, there was no effect on plaque growth or
stability.
16 MMP-7 gene deletion may have other effects on other
cell types, apart from VSMCs, within the plaques which are beneﬁcial
for plaque stability or may have other effects on arterial physiology
that counteract the beneﬁcial changes in VSMC content. For
example, MMP-7 has been implicated in the maintenance of arterial
tone, and therefore MMP-7 knockout mice may suffer increased
tensile force across the ﬁbrous cap as a result of reduced medial
tone.
41 Hence, the greater stability conferred on the lesion by
increased VSMCs may be negated by increased strain on the ﬁbrous
cap.
In summary, we have shown for the ﬁrst time that MMP-7 activity is
up-regulated during apoptosis of VSMCs. Moreover, we have
observed that MMP-7 causes cleavage of N-cadherin which is associ-
ated with increased VSMC apoptotic rates. We propose that MMP-7
may play a key role in atherosclerotic plaque development and
rupture via N-cadherin cleavage and induction of VSMC apoptosis.
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